Elevated Soluble Lectin-like oxidized LDL Receptor 1 (sLOX1) levels in sickle cell patients
Sickle-cell disease is characterized by chronic oxidative stress status with the resulting intense lipid
peroxidation, and among the generated metabolites is the oxidized LDL. The latter thus modified are no longer
recognized by the native receptors of LDL but by other types of receptors called “scavenger receptors”, among
which are LOX-1 (lectin-like oxidized LDL receptor). The capture of oxidized LDLs by vascular cells via
scavenger receptors is a crucial step in the initiation and progression of atherosclerosis. Like most surface
receptors, LOX-1 can be released in soluble form by proteolytic cleavage and this soluble form (sLOX-1) could
be a serum marker in the monitoring of oxidative and/or inflammatory diseases such as Sickle cell disease. The
objective of this work is to evaluate serum levels of sLOX-1 in sickle-cell patients and compare them to a control
population. Our study involved 80 subjects, including 48 sickle-cell anemia and 32 controls. sLOX-1 was
quantified using an Elisa method according to the manufacturer's instructions (Cloud-Clone Corp, Houston,
USA) and other biochemical parameters on the Cobas 6000 (Roche, Mannheim, Germany). Our results showed
serum levels of sLOX-1 significantly higher in sickle-cell patients population compared to controls (p <0.05).
Moreover, sickle-cell patients had a higher risk of having increased sLOX1 (OR = 1.23).The high levels of
sLOX-1 found in our study confirm our hypothesis and may reflect an increase in LOX-1 receptor expression
during sickle-cell anemia.
Auteur(s) : CISSE F, SECK M, LAMKINSI T, KANDJI PM, SALL A NDIAYE A, SAMBA A, THIAM S, DIALLO AGNE F, DIATTA A, SALL ND, TOURÉ M.
Pages : 83-88
Année de publication : 2017
Revue : Asian Journal of Biochemical and Pharmaceutical Research.
N° de volume : 7 (1)
Type : Article
Mise en ligne par : CISSE Fatou